<DOC>
	<DOCNO>NCT00497601</DOCNO>
	<brief_summary>The purpose study : 1 . To evaluate Safety Efficacy four different short-course regimen Amphotericin B emulsion treatment Kala-azar ( visceral leishmaniasis ) subject either treatment naive treatment resistant antileishmanial drug except amphotericin B containing preparation . 2 . To assess safety efficacy single-bolus infusion Amphotericin B emulsion treatment Kala-azar .</brief_summary>
	<brief_title>A Phase II Study To Assess Safety Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar</brief_title>
	<detailed_description>1 . To evaluate Safety Efficacy four different short-course regimen Amphotericin B emulsion treatment Kala-azar ( visceral leishmaniasis ) subject either treatment naive treatment resistant antileishmanial drug except amphotericin B containing preparation . 2 . To assess safety efficacy single-bolus infusion Amphotericin B emulsion treatment Kala-azar . Subjects administer study drug either follow four dose level ascend manner , start first dosage regimen : - 7.5 mg/kg day 1 day3 ( Regimen 1 ) - 10 mg/kg day 1 , follow 5 mg/kg day 3 ( Regimen 2 ) - 12.5 mg/kg day 1 , follow 2.5 mg/kg day 3 ( Regimen 3 ) - Single-bolus infusion 15 mg/kg 2-4 hour day 1 ( Regimen 4 )</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>1 . Male female subject 18 year 65 year age ( inclusive ) . 2 . Subject/subject 's legally acceptable representative willing able give write informed consent participate study . 3 . Treatment naive subject symptoms and/or sign visceral leishmaniasis parasitological confirmation Kalaazar ( splenic bone marrow aspirate smear examination ) . If subject previously treat antileishmanial drug except amphotericin B containing preparation , enrol study clinical parasitological evidence disease unresponsive adequate treatment drug , appropriate wash period 1 . Subjects past history treatment Amphotericin B Kalaazar . 2 . Subjects positive HIV infection . 3 . Concomitant life threaten serious disease . 4 . Concurrent malaria ( malarial parasite test negative prior study treatment administration ) , tuberculosis bacterial pneumonia . 5 . Haemoglobin &lt; 6 gm/dl , total leukocyte count &lt; 1,500/cmm , platelet count &lt; 50,000/cmm 6 . Abnormal liver renal function ( BUN serum creatinine &gt; 1.5 time upper limit normal ( ULN ) , AST/ALT &gt; 2.5 time ULN , bilirubin &gt; 1.5 time ULN ) . 7 . Pregnant nursing woman . 8 . Known hypersensitivity Amphotericin B inactive ingredient study drug formulation . 9 . Subjects receive medication prohibit study protocol . 10 . Evidence significant haematological , cardiac , hepatic , renal , respiratory , neurological metabolic disease condition , opinion investigator , might interfere evaluation study objective . 11 . Simultaneous participation another trial receive investigational product &lt; 30 day prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Visceral Leishmaniasis</keyword>
	<keyword>Amphotericin B</keyword>
	<keyword>Fat emulsion</keyword>
</DOC>